Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — Investor Presentation (November 2025)
30 slides from Nasus Pharma's investor presentation, November 2025
Slide 1: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Company Presentation – Novemb
Slide 2: Forward Looking Statements; Disclaimer
Forward Looking Statements; Disclaimer This presentation of Nasus Pharma Ltd. (the “Company”, “Nasus” or “Nasus Pharma”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities law. Words such as “expects,” “intends,” “pla
Slide 3: Company Highlights
Company Highlights Nasus is Uniquely Positioned to Address Medical Emergencies via Intranasal Drug Delivery NS002 was designed to address Proprietary Nasax powder Use of well-known active limitations of injectable technology aims to enhance pharmaceutical ingredients Epinephrine, with a needle-free,
Slide 4: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Addressing Significant Medical Emergencies Drug Candidate Molecule Indication Preclinical Phase 1 Phase 2 Pivotal Trial Next Milestone Results from Phase Phase 2 single dose PK study completed in March 2023 2 repeated dose NS002 Epineph
Slide 5: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of nasal cavity; The greater intranasal absorption area enables faster delivery and higher maximal drug concentration compared to liquid formulations Liquid formulation Powder formulation Liquid Spray
Slide 6: NS002: Intranasal Epinephrine
NS002: INTRANASAL EPINEPHRINE
Slide 7: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in ~1% of cases1 The standard of care for anaphylaxis is Epinephrine – this is typically self-administered via an Epinephrine auto-injector (EAI) or given via intramuscular (IM) injection by a healthcare
Slide 8: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market Estimated prevalence of anaphylaxis ~1-3% among the global population1 ~$2.3B Global Epinephrine market in 20242 ~40M Patients with type 1 allergies in the U.S.3 +6.5% From 2010 to 20233 CAGR Patients experience severe type I ~20M allergic reactio
Slide 9: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine The proposed solution: NS002 Autoinjectors1 with a 12-18 month Product candidate aims to offer shelf-life a needle-free solution, longer shelf-life, easily administered Large and bulky to carry2 15cm by trained professionals and
Slide 10: NS002: Completed Milestones
NS002: Completed Milestones Completed Completed NS002 NS002/EpiPen single pilot study dose PK Phase 2 study Q3 2021 Q2 2022 Q1 2023 Pre-IND meeting w/ FDA 10
Slide 11: NS002: Pilot Study Overview
NS002: Pilot Study Overview Study goal: Test NS002’s Epinephrine bioavailability following allergenic challenge PK/PD measurements: plasma Epinepherine, Tmax, T100, AUC, SBP, HR 12 healthy adults with allergic rhinitis (9 male, 3 female) Screening: positive to skin allergen test Period 1 Period 2 2-
Slide 12: Pilot Study Results Show NS002 Epinephrine Absorbed Faster than EpiPen
Pilot Study Results Show NS002 Epinephrine Absorbed into Bloodstream Faster than EpiPen Pilot Study Pharmacokinetics (PK) Plasma epinephrine – geometric mean – 60 min. n=12 12
Slide 13: NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption
NS002 Pilot Study Demonstrated Faster and Higher Maximal Epinephrine Absorption Compared to EpiPen Pilot study PK – baseline corrected time medians Area Under Curve Tmax median (min.) n=12 n=12 20.00 16.50 15.00 Tmax (min.) 9.00 8.98 10.00 5.99 5.00 2.50 0.00 EpiPen Nasus 1.6mg Nasus Nasus 3.2mg Nas
Slide 14: NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen
NS002 PD Results Demonstrated Comparable Epinephrine Activity to EpiPen Pilot study pharmacodynamics (PD) Systolic Blood Pressure n=12 125 120 SBP (mm Hg) EpiPen 115 Nasus 1.6mg normal condition 110 Nasus 1.6mg allergenic challenge 105 Nasus 3.2mg normal condition Nasus 3.2mg allergenic challenge 10
Slide 15: NS002: Phase 2 Study Design
NS002: Phase 2 Study Designed to Assess Safety and Tolerability, Test Bioavailability, and Optimize Dose for Phase 3 1 week 1 week Arm 1: N=6 B C A Nasus spray 3.6mg Nasus spray 4.0mg On each dosing day: EpiPen in one nostril in one nostril Screening PK sampling: 12 healthy -1 to 2hr. (13 samples) v
Slide 16: Phase 2 Study: More Patients Achieved Therapeutic Threshold at 6 Minutes
Phase 2 Study: More Patients Achieved Hemodynamic Therapeutic Threshold of Epinephrine by NS002 Compared to EpiPen at 6 Minutes Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects 6min EpiPen 55 % Nasus 3.6mg 72 % Nasus 4.0mg 91% Proportion of subjects achieving clinical threshold of 1
Slide 17: Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen
Phase 2 Study: NS002 Achieves Faster Epinephrine Plasma Concentration than EpiPen Mean AUC0-4min +SD n=12 Mean AUC0-10min +SD n=12 70 140 60 120 Mean AUC h*pg/mL Mean AUC h*pg/mL 50 100 40 80 27.44 63.96 30 50.99 60 20 14.17 40 27.38 10 5.85 20 0 Phase 2 EpiPen Nasus 3.6mg Nasus 4.0mg 0 EpiPen Nasus
Slide 18: Phase 2 Study: Faster Absorption and Greater Concentration Compared to EpiPen
Phase 2 Study: NS002 Achieves Faster Absorption and Greater Concentration of Epinephrine Compared to EpiPen – Including Time to Hemodynamic Therapeutic Threshold 100pg/ml Phase 2 Results - Cmax, Tmax and T100pg/mL Tmax (median, minutes) n=12 T100pg/mL (median, minutes) n=12 Cmax (Geometric mean + SD
Slide 19: Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen
Phase 2 Study: NS002 Demonstrated Comparable Epinephrine Activity to EpiPen Heart Rate Heart Rate n=12 Systolic Blood Pressure n=12 140 90 130 85 Systolic BP (mean) Phase 2: 80 HR (mean) 120 PD results 110 75 70 100 65 90 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Time (min.) Time (min.) Respiratio
Slide 20: NS002: Phase 2 Results Summary
NS002: Phase 2 Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors 01 NS002 reached the hemodynamic therapeutic plasma threshold faster than EpiPen 02 Maximum epinephrine absorption (Tmax) achieved significantly faster compared to EpiPen 03 Nasax powder was well tole
Slide 21: The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine ARS Pharma1 Orexo3 Aquestive4 Nasus Pharma5 (Market Cap $885M) (Market Cap SEK1.3B) (Market Cap $825M) (Market Cap $70M*) PK Parameters EpiPen5 Neffy (nasal spray) OX640 (nasal powder) ANAPHYLM (subling
Slide 22: Progression of Anaphylaxis + Epinephrine Onset of Action
Progression of Anaphylaxis + Epinephrine Onset of Action A Medical Emergency Where Every Second Counts and Speed Matters Nasus FMX1002 ARS-1 Neffy Tmax = 10 min1 Tmax = 30 min2 0 5min 10min 15min 20min 25min 30min Time of Drug Administration Serious patient discomfort increases the risk of hospitali
Slide 23: NS002: Clear Roadmap to NDA
NS002: Clear Roadmap to NDA • Following FDA guidance based on the 505b2 regulatory pathway • Demonstration of comparable PK/PD to EpiPen only requirement for regulatory approval • Repeated dose Ph2 study initiated in November 2025; interim readout Q1 2026 • Pivotal trial expected to initiate Q3 2026
Slide 24: NS002: Phase 2 Study Designed to Compare Bioavailability and PK of Repeat Dosing
NS002: Phase 2 Study Designed to Compare Bioavailability and PK of Repeat Dosing Results of the first pre-planned interim analysis expected in Q1 2026 Week 7: Week 5: Nasal allergic 2xNS002 4mg challenge L+L nostril 2xNS002 4mg Week 1: L+L nostril Week 4: Group 1 Nasal allergic Week 2: Week 3: 2xEpi
Slide 25: NS001: Intranasal Naloxone
NS001: INTRANASAL NALOXONE 25
Slide 26: Pivotal Study Validated the Superiority of Powder over Liquid
Pivotal Study Validated the Superiority of Powder over Liquid, Demonstrating Nasax Platform Delivers Naloxone Faster Compared to Narcan In our phase 3 (n=42) intranasal naloxone study (NS-001), our formulation provided faster delivery and higher mean absorption of naloxone compared to Narcan The res
Slide 27: Robust Patent Portfolio
Robust Patent Portfolio Country Filed Patent No./ Publication No. Grant Date/ Pub. Date Status Expiration Date(2) USA 8/20/2017 Term Ended PCT(1) 8/19/2018 WO 2019/038756 A1 National Phase entered 8/19/2038 Australia 8/19/2018 Grant Fee Paid 8/19/2038 Canada 8/19/2018 Office Action due: 10/22/2024 8
Slide 28: Nasus is Uniquely Positioned to Address Medical Emergencies
Proprietary Nasax powder technology designed to enhance intranasal drug absorption Lead product candidate NS002 is a needle-free, convenient, easily administered aiming to offer an alternative to Epinephrine autoinjector, directly addressing the currently unmet need Nasus is Uniquely Positive Phase
Slide 29: Leadership Team
Leadership Team Udi Gilboa, Co-Founder & Executive Chairman Mr. Gilboa is a prominent serial life sciences entrepreneur and the co-founder of multiple medical device and pharmaceutical companies. He co-founded and served as director and CFO of BioBlast Ltd (NASDAQ: ORPN), Alcobra Ltd (NASDAQ: ADHD),
Slide 30: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE Ame